Jinny Tavee

ORCID: 0000-0001-7767-5346
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Sarcoidosis and Beryllium Toxicity Research
  • Peripheral Neuropathies and Disorders
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Long-Term Effects of COVID-19
  • Peripheral Nerve Disorders
  • Inflammatory Myopathies and Dermatomyositis
  • Hereditary Neurological Disorders
  • Botulinum Toxin and Related Neurological Disorders
  • Amyloidosis: Diagnosis, Treatment, Outcomes
  • Pain Mechanisms and Treatments
  • Prion Diseases and Protein Misfolding
  • Spine and Intervertebral Disc Pathology
  • Myasthenia Gravis and Thymoma
  • S100 Proteins and Annexins
  • Multiple Sclerosis Research Studies
  • Musculoskeletal pain and rehabilitation
  • Cardiovascular Syncope and Autonomic Disorders
  • Autoimmune Neurological Disorders and Treatments
  • Glycogen Storage Diseases and Myoclonus
  • Muscle and Compartmental Disorders
  • Vasculitis and related conditions
  • Nerve Injury and Rehabilitation
  • Infectious Encephalopathies and Encephalitis
  • Eosinophilic Disorders and Syndromes
  • Genetic Neurodegenerative Diseases

University of Colorado Denver
2021-2024

National Jewish Health
2021-2024

Northwestern University
2017-2021

Medical College of Wisconsin
2021

Cleveland Clinic
2009-2019

GTx (United States)
2019

Portsmouth Regional Hospital
2008

Naval Medical Center Portsmouth
2007

The Neurosarcoidosis Consortium Consensus Group, an expert panel of physicians experienced in the management patients with sarcoidosis and neurosarcoidosis, engaged iterative process to define neurosarcoidosis develop a practical diagnostic approach suspected neurosarcoidosis. This aimed consensus clinical definition enhance care encourage standardization research initiatives that address this disease.The work collaboration included review manifestations establishment diagnosis disorder....

10.1001/jamaneurol.2018.2295 article EN JAMA Neurology 2018-08-30

Small fiber neuropathy commonly affects patients with sarcoidosis and is often refractory to standard immunosuppressive therapies used for systemic disease. The clinical features of sarcoidosis-associated small (SSFN) its response medical therapy have not been described in a large population.We performed retrospective review SSFN seen at the Cleveland Clinic over 4-year period.SSFN was identified 143 individuals although other causes were found 28 cases. Of remaining 115 patients, 100 (87%)...

10.1016/j.rmed.2017.03.011 article EN publisher-specific-oa Respiratory Medicine 2017-03-09

During the COVID-19 pandemic, patients with neuromuscular disorders, especially autoimmune myasthenia gravis, might be at greater risk of worse outcomes than otherwise healthy people because an immunocompromised state related to immunotherapy and possible respiratory bulbar muscular weakness. However, cessation in neuroinflammatory disorders has severe risks as well.1Korsukewitz C Reddel SW Bar-Or A Wiendl H Neurological era COVID-19—looking for consensus literature.Nat Rev Neurol. 2020; 16:...

10.1016/s1474-4422(20)30413-0 article EN other-oa The Lancet Neurology 2020-11-16

Purpose: Sarcoidosis frequently is complicated by small nerve fiber loss (SNFL), which can be quantified using corneal confocal microscopy (CCM). Prior studies suggest that the innate repair receptor agonist cibinetide reverses loss. This phase 2b, 28-day, randomized trial of 64 subjects with sarcoid-associated SNFL and neuropathic pain assessed effect on area (CNFA) regenerating intraepidermal fibers (GAP-43+) as surrogate endpoints for disease modification, severity, functional capacity...

10.1167/iovs.16-21291 article EN cc-by-nc-nd Investigative Ophthalmology & Visual Science 2017-05-05

10.1097/maj.0b013e3182808781 article EN The American Journal of the Medical Sciences 2013-01-29

The objective of this study was to determine whether meditation affects pain and quality life in people with multiple sclerosis (MS) peripheral neuropathy (PN). A total 22 patients (10 MS, 12 PN) participated a weekly class over 2-month period. 18 controls (7 11 received standard care. Primary outcome assessments were based on the 36-item Short Form Health Status Survey (SF-36) visual analogue scale (VAS) for at baseline 2 months. Secondary measures included Neuropathy Impairment Score (NIS)...

10.7224/1537-2073-13.4.163 article EN International Journal of MS Care 2011-12-01

A 42-year-old man with refractory epilepsy experienced a 1-min generalized tonic-clonic seizure followed by persistent inspiratory stridor and cyanosis while being monitored in our monitoring unit (EMU). Although his cardiac parameters remained stable throughout the event, patient's respiratory status rapidly declined, despite urgent administration of oxygen via bag-valve-mask. He was subsequently intubated emergency code team, who noted severe laryngospasm trying to insert endotracheal...

10.1111/j.1528-1167.2008.01781.x article EN Epilepsia 2008-09-18

Polyneuropathy evaluation in older patients is often challenging due to conflicting data regarding normative values for peripheral nerve testing.We characterized the results of sural conduction studies, intraepidermal fiber density (IENFD), and quantitative sudomotor axon reflex testing (QSART) a prospective study 50 healthy subjects aged ≥60 years.Of subjects, 48 (96%) had an obtainable sensory action potential (SNAP). Using quantile regression, we estimated lower limit normal (LLN)...

10.1002/mus.23971 article EN Muscle & Nerve 2013-07-29

Abstract We diagnosed 66 peripheral nerve injuries in 34 patients who survived severe coronavirus disease 2019 (COVID-19). combine this new data with published case series re-analyzed here (117 injuries; 58 patients) to provide a comprehensive accounting of lesion sites. The most common are ulnar (25.1%), fibular (15.8%), sciatic (13.1%), median (9.8%), brachial plexus (8.7%) and radial (8.2%) nerves at sites known be vulnerable mechanical loading. Protection should prioritized the care...

10.1186/s12984-022-01089-1 article EN cc-by Journal of NeuroEngineering and Rehabilitation 2022-10-08

Following the 2004 ban of ephedra, which was linked to several cases stroke and myocardial infarction, manufacturers have marketed "ephedra-free" weight loss products that include active ingredient synephrine. Despite lack data on safety efficacy, synephrine is touted by its promoters as a "safe" alternative ephedra often combined with caffeine, in supplement Xenadrine-EFX. We report case left middle cerebral artery vasopasm young healthy patient setting Xenadrine-EFX use.

10.7205/milmed.173.7.708 article EN Military Medicine 2008-07-01
Coming Soon ...